Kanada - angielski - Health Canada

hoffmann-la roche limited - mycophenolate mofetil - capsule - 250mg - mycophenolate mofetil 250mg - immunosuppressive agents

Kanada - angielski - Health Canada

hoffmann-la roche limited - mycophenolate mofetil - tablet - 500mg - mycophenolate mofetil 500mg - immunosuppressive agents

Kanada - angielski - Health Canada

hoffmann-la roche limited - mycophenolate mofetil (mycophenolate mofetil hydrochloride) - powder for solution - 500mg - mycophenolate mofetil (mycophenolate mofetil hydrochloride) 500mg - immunosuppressive agents

Kanada - angielski - Health Canada

hoffmann-la roche limited - mycophenolate mofetil - powder for suspension - 200mg - mycophenolate mofetil 200mg - immunosuppressive agents

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hf acquisition co. llc, dba healthfirst - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride injection, usp is indicated for the following: • rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white [w-p-w] and lown-ganong- levine [l-g-l] syndromes). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. • temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (wolff-parkinson-white (w-p-w) and lown-ganong-levine (l-g-l) syndromes). in controlled studies in the united states, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flutter and/or fibrillation with a faster ventricular rate respond with a decrease in ventricular rate of at least 20%. conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. because a small fraction (<1%) of patients treated with verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation, and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole − see contraindications and warnings), the initial use of verapamil hydrochloride injection should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including d.c.-cardioversion capability (see adverse reactions, suggested treatment of acute cardiovascular adverse reactions). as familiarity with the patient's response is gained, use in an office setting may be acceptable. cardioversion has been used safely and effectively after verapamil hydrochloride injection. verapamil hydrochloride injection is contraindicated in: 1. severe hypotension or cardiogenic shock. 2. second- or third-degree av block (except in patients with a functioning artificial ventricular pacemaker). 3. sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). 4. severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). 5. patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and av conduction. 6. patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., wolff- parkinson-white, lown-ganong-levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. therefore, the use of verapamil in these patients is contraindicated. 7. ventricular tachycardia: administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (qrs ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. 8. known hypersensitivity to verapamil hydrochloride.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride injection, usp is indicated for the following: • rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white [w-p-w] and lown-ganong- levine [l-g-l] syndromes). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. • temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (wolff-parkinson-white (w-p-w) and lown-ganong-levine (l-g-l) syndromes). in controlled studies in the united states, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flutter and/or fibrillation with a faster ventricular rate respond with a decrease in ventricular rate of at least 20%. conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. because a small fraction (<1%) of patients treated with verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation, and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole − see contraindications and warnings), the initial use of verapamil hydrochloride injection should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including d.c.-cardioversion capability (see adverse reactions, suggested treatment of acute cardiovascular adverse reactions). as familiarity with the patient's response is gained, use in an office setting may be acceptable. cardioversion has been used safely and effectively after verapamil hydrochloride injection. verapamil hydrochloride injection is contraindicated in: 1. severe hypotension or cardiogenic shock. 2. second- or third-degree av block (except in patients with a functioning artificial ventricular pacemaker). 3. sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). 4. severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). 5. patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and av conduction. 6. patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., wolff- parkinson-white, lown-ganong-levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. therefore, the use of verapamil in these patients is contraindicated. 7. ventricular tachycardia: administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (qrs ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. 8. known hypersensitivity to verapamil hydrochloride.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil hydrochloride injection, usp is indicated for the following: • rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white [w-p-w] and lown-ganong- levine [l-g-l] syndromes). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. • temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (wolff-parkinson-white (w-p-w) and lown-ganong-levine (l-g-l) syndromes). in controlled studies in the united states, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flutter and/or fibrillation with a faster ventricular rate respond with a decrease in ventricular rate of at least 20%. conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. because a small fraction (<1%) of patients treated with verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation, and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole − see contraindications and warnings), the initial use of verapamil hydrochloride injection should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including d.c.-cardioversion capability (see adverse reactions, suggested treatment of acute cardiovascular adverse reactions). as familiarity with the patient's response is gained, use in an office setting may be acceptable. cardioversion has been used safely and effectively after verapamil hydrochloride injection. verapamil hydrochloride injection is contraindicated in: 1. severe hypotension or cardiogenic shock. 2. second- or third-degree av block (except in patients with a functioning artificial ventricular pacemaker). 3. sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker). 4. severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy). 5. patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and av conduction. 6. patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., wolff- parkinson-white, lown-ganong-levine syndromes) are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. therefore, the use of verapamil in these patients is contraindicated. 7. ventricular tachycardia: administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (qrs ≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. 8. known hypersensitivity to verapamil hydrochloride.

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - verapamil hydrochloride (unii: v3888oey5r) (verapamil - unii:cj0o37ku29) - verapamil is indicated for the treatment of supraventricular tachyarrhythmias, including: • rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (wolff-parkinson-white [wpw] and lown-ganong-levine [lgl] syndromes). when clinically advisable, appropriate vagal maneuvers (e.g., valsalva maneuver) should be attempted prior to verapamil administration. • temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation, except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (wolff-parkinson-white [wpw] and lown-ganong-levine [lgl] syndromes). in controlled studies in the u.s., about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil hydrochloride. uncontrolled studies reported in the world literature describe a conversion rate of about 80%. about 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in heart rate of at least 20%. conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. the effect of a single injection lasts for 30–60 minutes when conversion to sinus rhythm does not occur. because a small fraction (<1.0%) of patients treated with verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation with an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole—see contraindications and warnings), the initial use of intravenous verapamil hydrochloride should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including dc-cardioversion capability (see suggested treatment of acute cardiovascular adverse reactions). as familiarity with the patient’s response is gained, an office setting may be acceptable. cardioversion has been used safely and effectively after intravenous verapamil. verapamil hydrochloride injection is contraindicated in: 1. severe hypotension or cardiogenic shock 2. second- or third-degree av block (except in patients with a functioning artificial ventricular pacemaker) 3. sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker) 4. severe congestive heart failure (unless secondary to a supraventricular tachycardia amenable to verapamil therapy) 5. patients receiving intravenous beta-adrenergic blocking drugs (e.g., propranolol). intravenous verapamil and intravenous beta-adrenergic blocking drugs should not be administered in close proximity to each other (within a few hours), since both may have a depressant effect on myocardial contractility and av conduction. 6. patients with atrial flutter or atrial fibrillation and an accessory bypass tract (e.g., wolff-parkinson-white, lown-ganong-levine syndromes). these patients are at risk to develop ventricular tachyarrhythmia including ventricular fibrillation if verapamil is administered. 7. ventricular tachycardia. administration of intravenous verapamil to patients with wide-complex ventricular tachycardia (qrs≥ 0.12 sec) can result in marked hemodynamic deterioration and ventricular fibrillation. proper pretherapy diagnosis and differentiation from wide-complex supraventricular tachycardia is imperative in the emergency room setting. 8. known hypersensitivity to verapamil hydrochloride

Belgia - francuski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eli lilly benelux - insuline humaine, biosynthétique, conversion - suspension injectable - 100 iu/ml - insuline humaine, biosynthétique, conversion 100 ui/ml - insulin (human)

Belgia - francuski - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eli lilly benelux - insuline humaine, biosynthétique, conversion - solution injectable - 100 iu/ml - insuline humaine, biosynthétique, conversion 100 ui/ml - insulin (human)